SEMA4A Antibody

What is SEMA4A and why is it significant in immunological research?

SEMA4A (Semaphorin-4A) is a cell surface protein belonging to the semaphorin family that functions in both neural development and immune regulation. In the human immune system, SEMA4A is preferentially expressed on antigen-presenting cells (APCs) including myeloid dendritic cells (mDCs) and B cells. Its significance stems from its role in T-cell co-stimulation and its ability to drive Th2 immune responses in humans. Unlike its murine counterpart that promotes Th1 responses, human SEMA4A (hSEMA4A) significantly enhances production of Th2 cytokines (IL-4, IL-5, and IL-13) while inhibiting IFN-γ production in Th1-skewing conditions .

How can researchers detect SEMA4A expression in different cell populations?

Researchers can employ multiple complementary techniques to detect SEMA4A expression:

• Microarray gene expression analysis: Useful for initial screening across multiple cell populations to identify relative expression levels.

• Quantitative PCR (Q-PCR): Provides precise quantification of SEMA4A mRNA expression in specific cell types.

• Flow cytometry: Using specific anti-SEMA4A monoclonal antibodies to detect surface protein expression on intact cells.

• Immunohistochemistry: For visualization of SEMA4A expression in tissue samples, particularly useful for examining expression in pathological specimens such as asthmatic lung tissue .

When detecting SEMA4A in human samples, researchers should note that expression is highest in CD4+CD11c+ myeloid DCs, followed by B cells and memory Th2 cells, with minimal expression in naive T cells .

What are the key considerations when selecting anti-SEMA4A antibodies for research?

When selecting anti-SEMA4A antibodies, researchers should consider:

• Specificity: Ensure the antibody specifically recognizes human SEMA4A with minimal cross-reactivity, especially since human and murine SEMA4A have different functional properties.

• Application compatibility: Verify the antibody is validated for your specific application (flow cytometry, immunohistochemistry, blocking studies, etc.).

• Clone selection: Different clones may have different epitope specificity. For functional studies, select antibodies that can block the interaction between SEMA4A and its receptor ILT-4.

• Format requirements: Consider whether you need a purified antibody, Fc fusion protein, or fluorophore-conjugated version depending on your experimental design .

For blocking studies, researchers have successfully used anti-SEMA4A monoclonal antibodies to inhibit SEMA4A-mediated T-cell proliferation and cytokine production .

How can researchers effectively block SEMA4A-mediated signaling in experimental systems?

Blocking SEMA4A-mediated signaling requires strategic approaches depending on the experimental system:

• Monoclonal antibody blocking: Anti-SEMA4A monoclonal antibodies can be used to block SEMA4A-mediated T-cell proliferation in co-culture systems. Studies have shown that inclusion of anti-SEMA4A mAb completely blocks T-cell proliferation co-stimulated by SEMA4A-transfected L cells .

• Receptor competition approach: Soluble ILT-4-Fc fusion proteins can block CD4+ T-cell proliferation co-stimulated by SEMA4A in a dose-dependent manner by competing with membrane-bound ILT-4 for SEMA4A binding .

• Anti-receptor antibodies: Anti-ILT-4 antibodies can block SEMA4A-mediated CD4+ T-cell proliferation in a dose-dependent manner when T cells are co-cultured with SEMA4A-expressing cells .

When designing blocking experiments, researchers should include appropriate isotype controls (e.g., mouse IgG for anti-SEMA4A mAb studies) to confirm specificity of the blocking effect.

What are the critical controls needed when studying SEMA4A function in T cell differentiation experiments?

When studying SEMA4A's role in T cell differentiation, implement these critical controls:

• Cell type controls:

  • Compare SEMA4A effects on different T cell subsets (naive CD4+ T cells vs. memory Th2 cells)

  • Include unstimulated T cells as negative controls

• Stimulation controls:

  • SEMA4A-expressing cells vs. non-transfected parental cells

  • SEMA4A-Fc fusion proteins vs. human IgG controls

• Blocking controls:

  • Anti-SEMA4A mAb vs. isotype control antibodies

  • Titration of blocking antibodies to demonstrate dose-dependence

• Cytokine differentiation controls:

  • Th1-skewing conditions (anti-CD3, anti-CD28, anti-IL-4 mAb, and IL-12)

  • Th2-skewing conditions (anti-CD3, anti-CD28, anti-IFN-γ mAb, and IL-4)

• Transcription factor analysis:

  • Monitor GATA3 and T-bet expression to confirm Th2 vs. Th1 differentiation

  • Assess STAT6 phosphorylation as a downstream marker of Th2 signaling

What experimental approaches can determine the binding affinity between SEMA4A and its receptor ILT-4?

To determine binding affinity between SEMA4A and ILT-4, researchers can employ:

• Surface Plasmon Resonance (SPR): Provides real-time binding kinetics and affinity measurements between purified SEMA4A and ILT-4 proteins.

• Enzyme-Linked Immunosorbent Assay (ELISA): Useful for confirming binding between SEMA4A-Fc and ILT-4 under equilibrium conditions.

• Flow cytometry binding assays: SEMA4A-Fc fusion proteins can be used to detect binding to cell surface-expressed ILT-4 on different cell populations. Research has shown preferential binding of SEMA4A-Fc to CD45RO+CRTH2+CD4+ memory Th2 cells .

• Immunoprecipitation studies: Can confirm physical interaction between SEMA4A and ILT-4 in cellular contexts.

• Competitive binding assays: Using labeled and unlabeled proteins to determine specificity and relative binding affinity.

Researchers should note that IL-4 treatment increases ILT-4 expression on activated T cells in a dose-dependent manner, which may affect experimental outcomes when studying this receptor-ligand interaction .

How does SEMA4A expression differ in diseased versus healthy tissues, and what methodologies best capture these differences?

SEMA4A expression shows significant differences between diseased and healthy tissues, particularly in allergic and malignant conditions:

• Allergic asthma: Both Q-PCR and immunohistochemical staining have demonstrated significantly higher SEMA4A expression in asthmatic lung tissue compared to healthy lung tissue. SEMA4A localizes to clusters of infiltrating cells in asthmatic lung, and within these infiltrates, CD4+ T cells express ILT-4 (the SEMA4A receptor) .

• Multiple myeloma: Cell surface expression of SEMA4A in primary myeloma cells exceeds that of BCMA and other CAR-T targets, as determined by plasma membrane fractionation followed by mass spectrometry. Flow cytometry confirms this finding and demonstrates that SEMA4A expression is more ubiquitous than BCMA across cell populations of individual patients .

To effectively capture these differences, researchers should employ:

• Quantitative PCR for mRNA expression

• Flow cytometry for cellular distribution analysis

• Immunohistochemistry for spatial distribution in tissues

• Plasma membrane fractionation with mass spectrometry for precise quantification of surface expression levels

What considerations should guide the development of SEMA4A-targeting therapeutic antibodies?

When developing SEMA4A-targeting therapeutic antibodies, researchers should consider:

• Target expression pattern: SEMA4A is expressed on immune cells including DCs and B cells, but also on pathological cells like myeloma cells. Therapeutic development must account for both on-target/on-tumor and on-target/off-tumor effects .

• Functional mechanism: Determine whether the antibody should block SEMA4A-ILT-4 interaction (potentially useful for allergic/Th2 diseases) or mediate cytotoxicity (for malignancies expressing SEMA4A).

• Epitope selection: Critical for both functional efficacy and safety. Antibodies targeting different SEMA4A epitopes may have distinct functional consequences.

• Format optimization: Consider different antibody formats (IgG, Fab, bispecific) based on the therapeutic goal.

• Potential for antibody-drug conjugates: SEMA4A has been described as an effective and safe antibody-drug conjugate target in myeloma .

• Immune modulation: Consider how targeting SEMA4A may affect immune responses, particularly given its role in T cell co-stimulation and Th2 differentiation .

What methodological approaches should be considered when developing SEMA4A CAR-T cells for multiple myeloma?

Developing SEMA4A CAR-T cells for multiple myeloma requires consideration of several methodological approaches:

• Target validation:

  • Confirm SEMA4A expression in target cells using flow cytometry

  • Perform plasma membrane fractionation with mass spectrometry to quantify surface expression

  • Compare SEMA4A expression to established targets like BCMA

  • Assess expression consistency across patient samples and in potential escape variants

• CAR design optimization:

  • Test multiple SEMA4A-binding domains for optimal affinity and specificity

  • Evaluate different costimulatory domains (CD28, 4-1BB, etc.) for enhanced persistence and efficacy

  • Consider dual-targeting approaches (SEMA4A + BCMA) to prevent antigen escape

  • Incorporate safety switches or conditional activation domains

• Functional testing:

  • Assess cytokine production profiles of SEMA4A CAR-T cells

  • Evaluate cytotoxicity against SEMA4A-expressing myeloma cells

  • Test efficacy against BCMA-negative myeloma cells that express SEMA4A

  • Ensure suitable engineering modifications to prevent fratricide (as SEMA4A can be expressed on activated T cells)

• Safety assessment:

  • Evaluate potential on-target/off-tumor effects given SEMA4A expression on some immune cells

  • Test against a panel of normal tissues to predict potential toxicities

  • Consider dual-receptor approaches requiring recognition of two targets for full activation

How does SEMA4A antibody-based research differ between its applications in immunology versus oncology?

SEMA4A antibody research differs significantly between immunology and oncology applications:

In immunology, researchers focus on SEMA4A's role in driving Th2 responses and potential intervention in allergic conditions like asthma . In oncology, SEMA4A is investigated as a target for antibody-drug conjugates and CAR-T therapies, particularly in multiple myeloma where it may complement or provide an alternative to BCMA-targeting approaches .

How can researchers address the technical challenges of detecting low-level SEMA4A expression in specific cell populations?

To overcome challenges in detecting low-level SEMA4A expression, researchers should consider:

• Signal amplification techniques:

  • Use tyramide signal amplification for immunohistochemistry

  • Employ fluorescent secondary antibody systems with higher sensitivity

  • Consider biotin-streptavidin detection systems for enhanced signal

• Enrichment approaches:

  • Perform cell sorting to enrich for populations of interest before analysis

  • Use magnetic bead separation to isolate specific cell subsets

• Optimized antibody selection:

  • Test multiple anti-SEMA4A antibody clones to find those with highest sensitivity

  • Use directly conjugated antibodies to reduce background

  • Consider recombinant antibodies for consistent performance

• Advanced flow cytometry:

  • Implement spectral flow cytometry to better resolve dim populations

  • Use fluorochromes with higher stain index for the SEMA4A channel

  • Include robust gating strategies with appropriate controls

• Transcript analysis:

  • Consider single-cell RNA sequencing for heterogeneous populations

  • Use digital PCR for absolute quantification of low-abundance transcripts

  • Implement nested PCR approaches for enhanced sensitivity

When analyzing clinical samples, researchers should note that SEMA4A expression may be enhanced in certain pathological states, such as asthmatic lung tissue or myeloma cells, compared to normal cell counterparts .

How should researchers interpret contradictory data regarding SEMA4A function between human and murine systems?

When interpreting contradictory data between human and murine SEMA4A systems, researchers should:

• Acknowledge fundamental differences: Human SEMA4A drives Th2 responses while murine Sema4A promotes Th1 responses. This represents a true biological difference rather than experimental artifact .

• Consider receptor differences: Murine Sema4A binds to T-cell immunoglobulin and mucin domain protein 2 (Tim-2), while human SEMA4A binds to Immunoglobulin-like transcript 4 (ILT-4). These different receptor interactions likely explain the divergent functional outcomes .

• Examine experimental conditions systematically:

  • Compare identical stimulation conditions between species

  • Assess cytokine production profiles comprehensively

  • Examine transcription factor expression (GATA3 vs. T-bet)

• Conduct cross-species experiments:

  • Test human SEMA4A on murine cells and vice versa

  • Examine receptor binding patterns across species

• Contextual interpretation:

  • In mice, Sema4A-deficiency impairs Th1 responses and enhances Th2 responses to pathogens

  • In humans, SEMA4A promotes Th2 cytokine production and is highly expressed in asthmatic lung tissue

• Translational implications:

  • Murine models may not accurately predict human responses to SEMA4A-targeting therapies

  • Humanized mouse models may be necessary for preclinical studies

This species difference underscores the importance of using human systems when studying SEMA4A for human applications, particularly in therapeutic development.